Publications
74
Citations
1,714
Est. group size
~11
Recurring co-author estimate
Active years
49
Publishing since 1978
Robert Neff's work centers on gynecologic cancers, particularly ovarian and endometrial cancer, spanning clinical trials of new drug therapies, genomic analysis of tumors, and studies of how healthcare access (like physician availability) and care delivery models (such as telemedicine and enhanced recovery programs) affect patient outcomes. This research blends clinical oncology with health-services and outcomes research relevant to cancer care delivery.
Publication output has fluctuated over the past decade, with an early peak in 2017, a lull in subsequent years, and modest but steady activity of a few papers per year more recently.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer.
Journal of Clinical Oncology · 2024
- TriHealth Cancer Institute’s collaboration with the Tempus AI TIME program impact on clinical trial operations and enrollment.
Journal of Clinical Oncology · 2024
- Analysis of inactivating TSC1 and TSC2 alterations in a real-world patient population with advanced gynecologic cancers in the Foundation Medicine genomic database
Gynecologic Oncology · 2024
- Association of Physician Densities and Gynecologic Cancer Outcomes in the United States
Obstetrical & Gynecological Survey · 2023
- Patient perspectives of telemedicine in gynecologic oncology during COVID
Gynecologic Oncology Reports · 2022
- Association of Physician Densities and Gynecologic Cancer Outcomes in the United States
Obstetrics and Gynecology · 2022
- Impact of Physician Densities on Gynecologic Cancer Outcomes in the United States [A316]
Obstetrics and Gynecology · 2022
- The association of county level physician densities with SEER summary stage and five-year survival rates for gynecologic cancers
Gynecologic Oncology · 2021
- <p>Treatment of Attention Deficit Hyperactivity Disorder with Monoamine Amino Acid Precursors and Organic Cation Transporter Assay Interpretation [Retraction]</p>
Neuropsychiatric Disease and Treatment · 2020
- Treatment of Attention Deficit Hyperactivity Disorder with Monoamine Amino Acid Precursors and Organic Cation Transporter Assay Interpretation [Expression of Concern]
DOAJ (DOAJ: Directory of Open Access Journals) · 2020
- Future Technology in Healthcare
2018
- How Evidence-Based Recommendations May Direct Policy Decisions Regarding Appropriate Selection and Use of Dietary Ingredients for Improving Pain
Pain Medicine · 2017
- Enhanced recovery after surgery (ERAS) for ovarian cancer: Analyzing the cost effectiveness of a recovery program in primary cytoreductve surgery
Gynecologic Oncology · 2017
- Enhanced Recovery After Surgery for Ovarian Cancer Patients
2017
- Gynecologic Oncology×15
- Gynecologic Oncology Reports×3
- Journal of Clinical Oncology×3
- Obstetrics and Gynecology×2
- Therapeutic Advances in Medical Oncology×1
- Maria C. Bell
Medicine · Indiana University
- D. E. Cohn
Medicine · The Ohio State University
- Laura Chambers
Medicine · The Ohio State University
- Larry J. Copeland
Medicine · The Ohio State University
- Molly Morton
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile